Patents by Inventor Diljeet Singh Athwal

Diljeet Singh Athwal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20020042089
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Application
    Filed: May 15, 2001
    Publication date: April 11, 2002
    Applicant: Celltech Therapeutics Limited.
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6316227
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: November 13, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 6180377
    Abstract: The invention describes humanized antibodies having specificity for the epitope recognised by the murine monoclonal antibody L243. Also described are processes for preparing said antibodies and pharmaceutical compositions and medical uses of said antibodies.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: January 30, 2001
    Assignee: Celltech Therapeutics Limited
    Inventors: Susan Adrienne Morgan, John Spencer Emtage, Mark William Bodmer, Diljeet Singh Athwal
  • Patent number: 5998586
    Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 7, 1999
    Assignee: Celltech Therapeutics, Limited
    Inventors: Mark William Bodmer, Diljeet Singh Athwal, John Spencer Emtage
  • Patent number: 5994510
    Abstract: Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: November 30, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage, Mark William Bodmer
  • Patent number: 5929212
    Abstract: The invention provides recombinant antibody molecules comprising antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and which have anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanized antibody and may be a chimeric or CDR-grafted antibody. A method is disclosed for preparing CDR-grafted humanized antibodies in which, in addition to the CDR's, non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58, and 71 of the light chain variable region. The recombinant, especially the humanized, anti-CD3 antibodies may used for in vivo therapy or diagnosis.
    Type: Grant
    Filed: September 3, 1993
    Date of Patent: July 27, 1999
    Assignee: Celltech Therapeutics Limited
    Inventors: Linda Kay Jolliffe, Robert Allan Zivin, John Robert Adair, Diljeet Singh Athwal
  • Patent number: 5859205
    Abstract: CDR-grafted antibody heavy and light chains comprise acceptor framework and donor antigen binding regions, the heavy chains comprising donor residues at at least one of positions (6, 23) and/or (24, 48) and/or (49, 71) and/or (73, 75) and/or (76) and/or (78) and (88) and/or (91). The CDR-grafted light chains comprise donor residues at at least one of positions (1) and/or (3) and (46) and/or (47) or at at least one of positions (46, 48, 58) and (71). The CDR-grafted antibodies are preferably humanised antibodies, having non human, e.g. rodent, donor and human acceptor frameworks, and may be used for in vivo therapy and diagnosis. A generally applicable protocol is disclosed for obtaining CDR-grafted antibodies.
    Type: Grant
    Filed: September 7, 1994
    Date of Patent: January 12, 1999
    Assignee: Celltech Limited
    Inventors: John Robert Adair, Diljeet Singh Athwal, John Spencer Emtage